Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis

Rheumatology (United Kingdom)

Volumn 54, Issue 2, 2015, Pages 210-218

  Eseonu, Onyedikachi I ^a   De Bari, Cosimo ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Chemokines; Chemotaxis; Homing; Mesenchymal stem cells; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1; CHEMOKINE; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN;

ARTHRITIS; CELL HOMING; HUMAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; ARTHRITIS, RHEUMATOID; CELL COMMUNICATION; CELL MOTION; MESENCHYMAL STROMA CELL; OSTEOARTHRITIS; PHYSIOLOGY; PROCEDURES;

ARTHRITIS, RHEUMATOID; CELL COMMUNICATION; CELL MOVEMENT; CHEMOKINES; HUMANS; MEMBRANE PROTEINS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOARTHRITIS; PLATELET-DERIVED GROWTH FACTOR;

EID: 84925582106     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu377     Document Type: Review

References (74)

1. Royal College of General Practitioners, Birmingham Research Unit. Annual Prevalence Report, 2007. http://www.rcgp.org.uk/clinical-and-research/~/media/Files/CIRC/CIRC-76-80/BRU_Annual_prevalence_report_2007.ashx (31 August 2014, date last accessed).
2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094–108.
3. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403–12.
4. Santaguida PL, Hawker GA, Hudak PL et al. Patient characteristics affecting the prognosis of total hip and knee joint arthroplasty: a systematic review. Can J Surg 2008;51:428–36.
5. Prokopetz JJ, Losina E, Bliss RL et al. Risk factors for revision of primary total hip arthroplasty: a systematic review. BMC Musculoskelet Disord 2012;13:251.
6. Corbett KL, Losina E, Nti AA, Prokopetz JJ, Katz JN. Population-based rates of revision of primary total hip arthroplasty: a systematic review. PLoS One 2010;5: e13520.
7. Yue EJ, Cabanela ME, Duffy GP, Heckman MG, O'Connor MI. Hip resurfacing arthroplasty: risk factors for failure over 25 years. Clin Orthop Relat Res 2009;467: 992–9.
8. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–7.
9. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001;44:1928–42.
10. De Bari C, Dell'Accio F, Vanlauwe J et al. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum 2006;54:1209–21.
11. Dell'Accio F, De Bari C, Luyten FP. Microenvironment and phenotypic stability specify tissue formation by human articular cartilage-derived cells in vivo. Exp Cell Res 2003; 287:16–27.
12. Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13: 4279–95.
13. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991;9: 641–50.
14. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970;3:393–403.
15. Behrens P, Bitter T, Kurz B, Russlies M. Matrix-associated autologous chondrocyte transplantation/implantation (MACT/MACI)—5-year follow-up. Knee 2006;13:194–202.
16. Kreuz PC, Muller S, Freymann U et al. Repair of focal cartilage defects with scaffold-assisted autologous chondrocyte grafts: clinical and biomechanical results 48 months after transplantation. Am J Sports Med 2011;39: 1697–705.
17. Zheng MH, Willers C, Kirilak L et al. Matrix-induced autologous chondrocyte implantation (MACI): biological and histological assessment. Tissue Eng 2007;13:737–46.
18. Kon E, Verdonk P, Condello V et al. Matrix-assisted autologous chondrocyte transplantation for the repair of cartilage defects of the knee: systematic clinical data review and study quality analysis. Am J Sports Med 2009; 37(Suppl 1):156S–66S.
19. Mahmood A, Lu D, Lu M, Chopp M. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 2003;53:697–702, discussion 703.
20. Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407–11.
21. Sullivan C, Barry FP, Ritter T et al. Allogeneic murine mesenchymal stem cells: migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig. Stem Cells Dev 2013;22: 3203–13.
22. Wu J, Sun Z, Sun HS et al. Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischemic rats. Cell Transplant 2008;16:993–1005.
23. Bocelli-Tyndall C, Bracci L, Spagnoli G et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology 2007;46:403–8.
24. Spaggiari GM, Moretta L. Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol 2013;91:27–31.
25. Ringe J, Strassburg S, Neumann K et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007;101:135–46.
26. Sordi V, Malosio ML, Marchesi F et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005;106:419–27.
27. Forte G, Minieri M, Cossa P et al. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 2006;24:23–33.
28. Neuss S, Becher E, Woltje M, Tietze L, Jahnen-Dechent W. Functional expression of HGF and HGF re-ceptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004;22:405–14.
29. Ponte AL, Marais E, Gallay N et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007;25:1737–45.
30. Lee JM, Kim BS, Lee H, Im GI. In vivo tracking of mesechymal stem cells using fluorescent nanoparticles in an osteochondral repair model. Mol Ther 2012;20:1434–42.
31. Wynn RF, Hart CA, Corradi-Perini C et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004;104:2643–5.
32. Kitaori T, Ito H, Schwarz EM et al. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum 2009;60:813–23.
33. Chen W, Li M, Cheng H et al. Overexpression of the mesenchymal stem cell Cxcr4 gene in irradiated mice increases the homing capacity of these cells. Cell Biochem Biophys 2013;67:1181–91.
34. Kanbe K, Takagishi K, Chen Q. Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum 2002;46:130–7.
35. Maurer M, von Stebut E. Macrophage inflammatory pro-tein-1. Int J Biochem Cell Biol 2004;36:1882–6.
36. Koch AE, Kunkel SL, Harlow LA et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994;93:921–8.
37. Boomsma RA, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One 2012;7:e35685.
38. Takano T, Li YJ, Kukita A et al. Mesenchymal stem cells markedly suppress inflammatory bone destruction in rats with adjuvant-induced arthritis. Lab Invest 2014;94: 286–96.
39. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005;115: 118–28.
40. Hulejova H, Baresova V, Klezl Z et al. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 2007;38: 151–6.
41. de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage 2012;20: 1484–99.
42. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313–26.
43. Harris Q, Seto J, O'Brien K et al. Monocyte chemotactic protein-1 inhibits chondrogenesis of synovial mesenchymal progenitor cells: an in vitro study. Stem Cells 2013;31: 2253–65.
44. Akahoshi T, Wada C, Endo H et al. Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. Arthritis Rheum 1993;36:762–71.
45. Koch AE, Kunkel SL, Harlow LA et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772–9.
46. Dwyer RM, Potter-Beirne SM, Harrington KA et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007;13:5020–7.
47. Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T. Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell 2008;2:566–75.
48. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991;88:9267–71.
49. DiSalvo J, Bayne ML, Conn G et al. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J Biol Chem 1995;270:7717–23.
50. Selvaraj SK, Giri RK, Perelman N et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003; 102:1515–24.
51. Park SJ, Kim KJ, Kim WU, Cho CS. Interaction of mesenchymal stem cells with fibroblast-like synoviocytes via cadherin-11 promotes angiogenesis by enhanced secretion of placental growth factor. J Immunol 2014;192: 3003–10.
52. Yoo SA, Yoon HJ, Kim HS et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Arthritis Rheum 2009;60:345–54.
53. Rosengren S, Corr M, Boyle DL. Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther 2010;12:R65.
54. Cipriani P, Marrelli A, Benedetto PD et al. Scleroderma mesenchymal stem cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis 2013;16:595–607.
55. Endres M, Neumann K, Haupl T et al. Synovial fluid recruits human mesenchymal progenitors from subchondral spongious bone marrow. J Orthop Res 2007; 25:1299–307.
56. Barbash IM, Chouraqui P, Baron J et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003;108:863–8.
57. Kraitchman DL, Tatsumi M, Gilson WD et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005;112:1451–61.
58. Schrepfer S, Deuse T, Reichenspurner H et al. Stem cell transplantation: the lung barrier. Transplant Proc 2007;39: 573–6.
59. Furlani D, Ugurlucan M, Ong L et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res 2009;77:370–6.
60. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12–20.
61. Sackstein R, Merzaban JS, Cain DW et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14:181–7.
62. Tang TT, Lu B, Yue B et al. Treatment of osteonecrosis of the femoral head with hBMP-2-gene-modified tissue-engineered bone in goats. J Bone Joint Surg Br 2007;89: 127–9.
63. Lieberman JR, Daluiski A, Stevenson S et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 1999;81: 905–17.
64. Dai KR, Xu XL, Tang TT et al. Repairing of goat tibial bone defects with BMP-2 gene-modified tissue-engineered bone. Calcif Tissue Int 2005;77:55–61.
65. Reddi AH. Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am 2001; 83(1 Suppl 1):S1–6.
66. Wei L, Sun X, Kanbe K et al. Chondrocyte death induced by pathological concentration of chemokine stromal cell-derived factor-1. J Rheumatol 2006;33:1818–26.
67. Chiu YC, Yang RS, Hsieh KH et al. Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes. Mol Pharmacol 2007;72:695–703.
68. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025–31.
69. Zhang Z, Ding Y, Li W, Song B, Yang R. Interleukin-17A-or tumor necrosis factor a-mediated increase in proliferation of T cells cocultured with synovium-derived mesenchymal stem cells in rheumatoid arthritis. Arthritis Res Ther 2013;15:R169.
70. Djouad F, Fritz V, Apparailly F et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005;52:1595–603.
71. Hughes C, Faurholm B, Dell'Accio F et al. Human singlechain variable fragment that specifically targets arthritic cartilage. Arthritis Rheum 2010;62:1007–16.
72. Dazzi F, Lopes L, Weng L. Mesenchymal stromal cells: a key player in 'innate tolerance'? Immunology 2012;137: 206–13.
73. Ohtaki H, Ylostalo JH, Foraker JE et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA 2008;105: 14638–43.
74. Constantin G, Marconi S, Rossi B et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009;27: 2624–35.